Applied Precision Cancer Medicine in Neuro-Oncology

[1]  A. Matheu,et al.  Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges , 2019, Cancers.

[2]  A. Klekner,et al.  Significance of liquid biopsy in glioblastoma - A review. , 2019, Journal of biotechnology.

[3]  Bo Zhang,et al.  A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNOC003: A report from the Pacific Pediatric Neuro‐Oncology Consortium , 2019, International journal of cancer.

[4]  Russell Bonneville,et al.  Implementing precision cancer medicine in the genomic era. , 2019, Seminars in cancer biology.

[5]  P. Keegan,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.

[6]  C. Brennan,et al.  Tracking Tumor Evolution in Glioma through Liquid Biopsies of Cerebrospinal Fluid , 2018, Nature.

[7]  Diane D. Liu,et al.  Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. , 2018, The Lancet. Oncology.

[8]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  M. Cowley,et al.  Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma , 2018, British Journal of Cancer.

[11]  Juxiang Chen,et al.  Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment , 2018, Translational oncology.

[12]  C. Grommes,et al.  Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas , 2017, Journal of Immunotherapy for Cancer.

[13]  G. Stoffels,et al.  Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease , 2017, Oncology reports.

[14]  I. König,et al.  What is precision medicine? , 2017, European Respiratory Journal.

[15]  C. Caeiro,et al.  Current Standards of Care in Glioblastoma Therapy , 2017 .

[16]  B. Nahed,et al.  Liquid biopsy for brain tumors , 2017, Expert review of molecular diagnostics.

[17]  Georg Langs,et al.  The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space , 2017, Nature Medicine.

[18]  S. Halford,et al.  ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM) , 2017 .

[19]  S. Choi,et al.  Molecular Testing of Brain Tumor , 2017, Journal of pathology and translational medicine.

[20]  Susan M. Chang,et al.  Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. , 2016 .

[21]  A. Ghazalpour,et al.  Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies , 2016, Oncotarget.

[22]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[23]  Timothy C Ryken,et al.  Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.

[24]  Michael C. Rusch,et al.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Buchfelder,et al.  Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment , 2015, Cancer science.

[26]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[27]  N. Iqbal,et al.  Imatinib: A Breakthrough of Targeted Therapy in Cancer , 2014, Chemotherapy research and practice.

[28]  C. Marosi,et al.  Response to imatinib as a function of target kinase expression in recurrent glioblastoma , 2014, SpringerPlus.

[29]  K. Aldape,et al.  Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.

[30]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[31]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[32]  M. Lindström,et al.  PDGF and PDGF receptors in glioma , 2012, Upsala journal of medical sciences.

[33]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[35]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Olson,et al.  Benefit of Temozolomide Compared to Procarbazine in Treatment of Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Performance Status, and Health Related Quality of Life , 2005 .

[37]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[38]  S. Devleeschouwer.  Current Standards of Care in Glioblastoma Therapy -- Glioblastoma , 2017 .

[39]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[40]  J. Olson,et al.  Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. , 2005, Cancer investigation.

[41]  C. Marosi,et al.  Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy , 2005, Journal of Neuro-Oncology.